Orpra 40 mg (Capsule (Enteric Coated))

Unit Price: ৳ 8.00

Medicine Details

Category	Details
Generic	Omeprazole
Company	Orbit pharmaceuticals ltd
Also available as	Orpra 20 mg capsule

Indications

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
As prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

Pharmacology

Omeprazole, a substituted benzimidazole, is an inhibitor of gastric acid secretion. It inhibits gastric acid secretion by blocking hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system in the gastric parietal cell. After oral administration, the onset of the antisecretory effect occurs within one hour, with the maximum effect occurring within two hours and inhibition of secretion lasts up to 72 hours. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days.

Dosage

20 mg once daily for 4 weeks in duodenal ulceration, 8 weeks in gastric ulceration
40 mg once daily for severe or recurrent cases
maintenance dose for recurrent duodenal ulcer, 20 mg once daily
in prevention of relapse in duodenal ulcer, 10-20 mg daily
20 mg once daily for 4 weeks, continued for further 4 weeks, if not fully healed
20 mg once daily is used as prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcers
20 mg once daily for 4 weeks, continued for further 4-8 weeks, if not fully healed; 40 mg once daily has been given for 8 weeks in gastro-esophageal reflux disease, refractory to other treatment; maintenance dose is 20 mg once daily
10-20 mg daily
10-20 mg once daily for 2-4 weeks
40 mg on the preceding evening, then 40 mg 2-6 hours before surgery
Initially 60 mg once daily for Zollinger-Ellison syndrome
Omeprazole is recommended at a dose of 20 mg twice daily in association with antimicrobial agents for Helicobacter pylori eradication regimen
If body-weight 10-20 kg, 10-20 -mg once daily for 4-12 weeks; if body-weight over 20 kg, 20-40 mg once daily for 4-12 weeks

Administration

Omeprazole lyophilized powder and water for injection is for intravenous administration only and must not be given by any other route
Omeprazole IV infusion should be given as an intravenous infusion over a period of 20-30 minutes or more

Interaction

Decreased intragastric acidity may reduce the absorption of ketoconazole during Orpra treatment
Orpra is metabolised in the liver through cytochrome P450 which can delay the elimination of diazepam, phenytoin and warfarin
Concomitant treatment with Orpra and clarithromycin can increase plasma concentrations
No evidence of an interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, cyclosporin, lidocaine, quinidine, estradiol, amoxycillin or antacids
No evidence of an interaction with piroxicam, diclofenac or naproxen
Simultaneous treatment with Orpra and digoxin in healthy subjects lead to a 10% increase in the bioavailability of digoxin as a consequence of the increased intragastric pH

Contraindications

Omeprazole is contraindicated in patients with known hypersensitivity to it. When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with omeprazole is instituted.

Side Effects

Skin rash, urticaria and pruritus
Photosensitivity, bullous eruption, erythema multiforme, angioedema and alopecia
Diarrhoea and headache
Gastrointestinal reactions like constipation, nausea/vomiting, flatulence and abdominal pain
Dry mouth, stomatitis and candidiasis
Paraesthesia
Dizziness, light headedness and feeling faint
Somnolence, insomnia and vertigo
Reversible mental confusion, agitation, depression and hallucinations
Arthritic and myalgic symptoms
Blurred vision, taste disturbance, peripheral oedema
Increased sweating, gynaecomastia, leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, anaphylactic shock
Malaise, fever, bronchospasm
Encephalopathy in patients with pre-existing severe liver disease
Increases in liver enzymes

Pregnancy & Lactation

Results from three prospective epidemiological studies indicate no adverse effects of Omeprazole on pregnancy or on the health of the fetus/newborn child. Omeprazole can be used during pregnancy.

Precautions & Warnings

Avoid concomitant use of clopidogrel and Orpra
Proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures
Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with Orpra

Therapeutic Class

Proton Pump Inhibitor

Storage Conditions

Keep in a dry place away from light and heat. Keep out of the reach of children.